This resistance could be attributed to a gene mutation in BCR::ABL that happens in 40 - 90% of the study by Yang et al. 23, it may be an epigenetic mechanism in Src family kinase or abnormal expression of tumor drug resistance-associated proteins such as IGF as illustrated in the study by El Fakih et al.24. Here, ABL1 is linked to neoplasm.